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Four challenge studies following vaccination of dogs with a multivalent vaccine containing canine
parvovirus (CPV-2b), adenovirus (CAV-1/-2) and distemper (CDV) are described. Six week old puppies
received a single vaccination while non-vaccinated control dogs received water. In each respective trial,
groups of dogs were challenged 21 days after vaccination with heterologous viral isolates. Clinical
observations, rectal temperature measurements, and blood and swab samples for analysis were collected
throughout the study.
Dogs in all studies had normal temperatures and general health up to challenge. Clinical signs of
infection and temperatures outside the normal range were observed in non-vaccinated dogs challenged
with CDV, CPV, CAV-1 and CAV-2; vaccinated dogs remained clinically normal after challenge. All dogs
were sero-negative prior to vaccination, non-vaccinated dogs remaining negative until challenge.
Vaccinated dogs all sero-converted by 21 days after vaccination, with further increases seen after
challenge. Non-vaccinated dogs sero-converted following challenge with CPV or CAV-2; no ﬁnal blood
samples were taken in the CDV and CAV-1 studies. Rectal swab analysis showed prevention of CPV
shedding in vaccinated compared to non-vaccinated dogs, and nasal swab analysis following CAV-2
challenge showed longer duration and higher amount of viral shedding for non-vaccinated dogs.
In conclusion, we demonstrated that a single administration of a minimum titre, multivalent vaccine to
dogs of six weeks of age is efﬁcacious and prevents clinical signs and mortality caused by CAV-1 and CDV;
prevents clinical signs and signiﬁcantly reduces virus shedding caused by CAV-2; and prevents clinical
signs, leucopoenia and viral excretion caused by CPV.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Domestic dogs are at higher risk of contracting infectious
diseases, and in particular viral infections, if they are not immune
to the speciﬁc agent [1]. The widespread use of vaccines has led to
reduced incidence of common infections; however, continuing
evolution of vaccine technology results in products of varying
efﬁcacy [2] or range of protection. Vaccines have been grouped into
core, non-core or non-recommended categories; with canine
distemper, canine parvovirus and canine adenovirus considered
core vaccine components recommended to be administered everythree years [3]. These recommendations have been expanded and
form the basis of the World Small Animal Veterinary Association
(WSAVA) Guidelines for the Vaccination of Dogs and Cats [4].
Canine parvovirus (CPV) infection of dogs results in a contagious
enteric disease leading to high rates of mortality or severe morbid-
ity [5]. All naïve dogs are susceptible to infection with those under
one year of age having the highest risk of developing severe disease.
Since CPV2 was ﬁrst identiﬁed [6], there have been multiple varia-
tions of virus strains which have increased in prevalence. Canine
parvovirus type 2a [7], CPV-2b [8] and CPV-2c have been identiﬁed
[9], and are becoming more frequently isolated [10,11]. Canine
adenovirus type 2 (CAV-2) infection ranges from essentially non-
apparent to a mild form of respiratory disease; however, the virus
is considered to be one of the main causes of infectious
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results in a more general infection, with predominant clinical signs
being nausea, vomiting and diarrhoea [12]. Although CAV-2 was
initially thought to be derived from CAV-1, later analysis [13]
revealed they are genetically distinct. Despite this, dogs vaccinated
with vaccines containing CAV-1 or CAV-2 were found to be cross
protected [14,15]. As vaccines containing CAV-1 do have safety
issues [12], current vaccines as recommended by the WSAVA [4]
contain CAV-2. Canine distemper virus (CDV) is another highly con-
tagious virus which results in acute to sub-acute systemic disease
and a high mortality rate in dogs [16], although the host range
[17] includes a variety of species. The introduction of efﬁcacious
vaccines has reduced the incidence of canine distemper disease in
dogs although the possibility still exists that infection outbreaks
can occur, even in vaccinated animals [16].
In this paper we describe the efﬁcacy of a new multivalent
canine vaccine containing the core viral components – CDV, CPV
and CAV – in addition to canine para-inﬂuenza, rabies and four
Leptospira interrogans and kirschneri serovar antigens. In four sepa-
rate trials, dogs free of antibodies to the vaccine antigens received
a single vaccination and then were challenged with different
strains of each core viral antigen (distemper, adenovirus 1 and 2,
and parvovirus). The impact of vaccination on clinical variables,
serology and for some components (CPV and CAV-1) re-isolation
of challenge virus was examined by comparing vaccinated dogs
to non-vaccinated dogs in each study.Materials and methods
This study reports the results of four separate trials with all
studies designed to be compliant with the respective European
Pharmacopeia monographs 01/2008:0448 (distemper), 01/2008:
1951 (adenovirus) and 01/2008:0964 (parvovirus). The studies
were carried out in accordance with the Act on Animal Health
and Animal Welfare of The Czech Republic, and had been approved
by Bioveta a.s. and Zoetis ethical review committees.
Animals
In the studies determining efﬁcacy to CDV, CAV-1 and CPV,
seven dogs aged 6 weeks old, were enrolled into each study with
ﬁve dogs vaccinated and two dogs receiving water for injection
acting as controls. In the CAV-2 study, 20 dogs were enrolled with
10 dogs vaccinated and 10 dogs receiving water for injection as
controls. All dogs were conﬁrmed to be free of antibodies (methods
described in laboratory analysis) against the respective challenge
virus.
Vaccine
An experimental vaccine batch was produced which contained
live CDV, CPiV, CAV-2, CPV-2b (DHPPi); inactivated L. interrogans
sv Canicola, Icterohaemorrhagiae and Bratislava, and L. kirschneri
sv Grippotyphosa, and rabies virus (L4R). The DHPPi component
was freeze-dried while the L4R component was a liquid containing
adjuvant (aluminium hydroxide). The control product was sterile
water. Administration (1 ml) was by the subcutaneous route
behind the left shoulder blade on day 0 using standard aseptic
technique. Where appropriate vaccine antigens were formulated
at minimum titre and maximum passage.
Challenge
The challenge isolates were different strains to the vaccine
antigens and had been used previously in validation studies. CDVisolate Snyder Hill was obtained from the American Type Culture
Collection; CAV-1 isolate Mirandola and the CAV-2 isolate
Manhattan were obtained from the Animal and Plant Health
Inspection Services at the Centre for Veterinary Biologics; and
CPV 2b isolate 212/98 was obtained from the University of Bari,
Italy. For the CDV (101 dilution of virus provided which was of
unknown titre) and CAV-1 (105.8 TCID50/mL) studies 1 mL of chal-
lenge material was administered by the intravenous route; for
CPV (106.8 TCID50/mL) a 2 mL dose was administered with 1 mL
orally and 1 mL intranasally (0.5 mL per nostril); for CAV-2
(105.3 TCID50/mL), 1 mL of challenge material was administered
intranasally.
Observations and samples
Rectal temperatures (C) of all animals were recorded on days-
2, -1, 0 (prior to and 4 h after vaccination) and then daily thereafter
for a period of seven days. Further measurements were recorded
on day 21 (prior to and 4 h after challenge administration), then
daily until the end of the study.
Clinical observations were performed once daily from day-2
until the end of the study. Clinical observations on days 0 and 21
were performed prior to vaccine and challenge strain administra-
tion respectively, with additional observations approximately 4 h
after challenge strain administration. Observations performed
following challenge administration assessed developing clinical
disease. However, for animal welfare reasons speciﬁc clinical
endpoints were deﬁned for each challenge whereby animals would
be euthanased prior to reaching end-stage clinical disease.
Blood samples were collected into plain blood tubes from each
animal prior to test material (vaccine or control) administration on
day 0, prior to challenge administration on day 21, and at the end
of the study on day 35 for CAV-2 and CPV or day 42 for CDV and
CAV-1. For the CPV study further blood samples (0.5–1 ml) for
white blood cell (WBC) counts were collected from each animal
4, 2 and 0 days before and then 3, 5, 7, 10, 12 and 14 days post-
challenge administration.
To determine virus shedding in the CPV study, faecal swabs
were collected into sterile tubes on day 21 before CPV-2b challenge
administration (before challenge) and then 3, 5, 7, 10, 12 and
14 days after CPV-2b challenge. In the CAV-2 study, two nasal swab
samples (one from each nostril) were collected into sterile tubes
from each animal prior to challenge administration on day 21
and then daily from day 23 (2nd day after challenge) until day
31 (10th day after challenge).
Laboratory analysis
Serum samples from the respective studies were examined for
the presence of antibodies to CDV, CPV-2, CPV-2b, CAV-1 and
CAV-2 by serum-neutralisation test. Brieﬂy, duplicate two-fold
dilutions of test and control sera in MEM cultivation medium were
prepared in micro titre plates; approximately 100 TCID50 of the
respective virus was added followed by incubation at 37 C for
1 h in 5% CO2. Susceptible cells (VERO – CDV; MDCK – CAV; CRFK
– CPV) were added as appropriate; with a further incubation at
37 C for 3–7 days in 5% CO2. The end point was assessed as the
serum dilution where more than 50% of the characteristic cyto-
pathic effect was attenuated. For the CPV analysis the haemagglu-
tination assay was used to deﬁnitively conﬁrm virus presence and
visualisation; the end point was assessed as the serum dilution
where inhibition of haemagglutination was observed.
For the CPV study, whole blood samples were analysed for leu-
kocyte counts by staining cells with T}urk’s solution and counting
them in a B}urkerusing standard counting chamber. Faecal samples
were examined for virus presence and titre by re-isolation on a
Table 1
Geometric mean antibody titres against canine distemper virus, by time period and
treatment group.
Treatment group Virus neutralising antibody titres
Day 0 Day 21 Day 42
Vaccinated (n = 5) <2 9.2 48.5
Control (n = 2) <2 <2 NA
NA – both control dogs were euthanased prior to sample collection day.
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and centrifuged, with supernatants diluted two-fold on microtitre
plates. The A72 cells were added (400–600,000 cells/well) and
plates incubated at 37 C in 5% CO2. After 5 to 7 days virus presence
was conﬁrmed by haemagglutination assay. Porcine erythrocytes
were added to all wells and plates were incubated for 1 h at 2–
8 C. The titre is calculated and expressed in TCID50/mL. For the
CAV-2 study nasal swab samples were examined for virus presence
and titre by virus re-isolation on MDCK cells.
Statistical analysis
Body temperatures were classiﬁed into hypothermic (<37.0 C),
normal (37.0 to 39.5 C) and hyperthermic (>39.5 C). Abnormal
clinical data and the number of days with abnormal clinical signs
were summarised for vaccinates and controls pre-challenge and
post challenge. Descriptive statistics for antibody titres against rel-
evant antigens including the geometric mean, minimum and maxi-
mumwere calculated for vaccinates and controls at each time point.
In the CPV study, for each animal the arithmetic mean of WBC
counts taken up to 4 days pre-challenge was calculated to obtain
the baseline value; post-challenge counts were compared with
the baseline value thereby calculating the percentage reduction.
Leucopoenia was deﬁned as a decrease in WBC greater than 50%
of the baseline value. The geometric mean of the maximum titres
excreted in faeces of control animals were calculated and com-
pared to the maximum titre excreted in faeces of each vaccinated
animal.
In the CAV-2 study clinical observations were scored and the
total clinical scores, the number of days of virus shedding, and
the AUC (area under the curve) of virus shedding in the challenge
phase of the study were calculated for each animal. The rank trans-
formed total clinical scores, number of days of virus shedding and
the logarithm transformed AUC values were analysed with a gen-
eral linear mixed model (ﬁxed effect was treatment, random
effects were pen, block within pen and residual). The mean and
median clinical scores were calculated for each treatment as well
as the minimum and maximum.Table 2
Geometric mean antibody titres against canine parvovirus type 2 and type 2b, by time
period and treatment group. Titres against CPV-2 and CPV-2b are expressed as the
reciprocal dilution of sera.
Treatment group CPV detected Virus neutralising antibody titre
Day 0 Day 21 Day 42
VN VN VN
Vaccinated (n = 5) CPV-2 <2 485.0 2940.7
Control (n = 2) <2 <2 1810.2
Vaccinated (n = 5) CPV-2b <2 3377.9 8914.4
Control (n = 2) <2 <2 3620.4
VN = virus neutralisation.Results
Canine distemper virus
No abnormal clinical observations were observed in the period
following administration of vaccine or control product. All dogs
remained in good health and their rectal temperatures stayed
within the physiological range (37.0 to 39.5 C). Following chal-
lenge both control dogs showed abnormal clinical signs due to
canine distemper infection, with fever, anorexia, apathy and gas-
trointestinal disturbances seen from three days after challenge.
Both dogs were subsequently euthanased nine and ten days after
challenge respectively due to progression of clinical signs in accor-
dance with pre-deﬁned welfare endpoints. No abnormal clinical
signs indicative of distemper infection or rectal temperatures out-
side the physiological range were observed in vaccinated dogs.
Antibody titres to CDV were ﬁrst detected in vaccinated dogs on
day 21 and continued to rise until day 42 when sampling ceased.
Controls remained sero-negative until after challenge on day 21,
as controls were euthanased prior to day 35 (study completion)
no ﬁnal (day 35) blood sample was obtained (Table 1).
Canine parvovirus
Following vaccination, one vaccinated dog developed a swelling
at the injection site. Furthermore, one control dog had atemperature below the lower limit (37.9 C) two days before and
six days after the administration of water for injection, which
was not thought clinically relevant in the context of this study.
No other abnormal clinical signs were observed in the pre-
challenge period. Following challenge both control dogs showed
typical clinical signs of canine parvovirosis such as apathy,
anorexia and diarrhoea from six days until 10 days after challenge.
A considerable decrease in temperature from 38.7 C to 37.0 C in
24 h was also observed in one control dog which was clearly
related to the challenge (data not shown). The vaccinated dogs
neither showed any abnormal clinical signs nor temperatures after
the challenge (data not shown).
Antibody titres to CPV-2 and CPV-2b were ﬁrst detected in vac-
cinated dogs on day 21 and continued to rise until day 42 when
sampling ceased. Controls remained sero-negative until after chal-
lenge on day 21, sero-converting by day 42 (Table 2).
Following challenge none of the vaccinated dogs showed any
decrease in WBC below 50% of the mean pre-challenge values.
The WBC counts of both control dogs decreased more than 50%
from pre-challenge values. 12 days post-challenge they had
decreased more than 60% from baseline, and were below the lower
limit of the normal physiological range (data not shown).
Results achieved for examination of faeces by virus re-isolation
are summarised in Table 3. No virus excretion was detected in the
vaccinated animals at any time point following challenge. Both
control animals excreted CPV from three to fourteen days after
challenge. When the samples were examined by haemagglutina-
tion assays (data not shown) small amounts of excreted CPV rang-
ing from 4 to 16 HAU were detected in three of ﬁve vaccinated
animals on one day between three to ﬁve days after challenge.
No virus excretion was observed in the remaining two vaccinated
animals and in any of the vaccinated animals from seven days after
challenge. Both control animals excreted CPV from three to four-
teen days after challenge.Canine adenovirus type 1
Following vaccination no abnormal clinical signs were observed
and the rectal temperatures of all dogs remained within the nor-
mal physiological range. After challenge, both control dogs showed
abnormal clinical signs due to canine hepatitis infection from ﬁve
Table 3
CPV re-isolation from faecal swab samples, by time period and treatment group. Titres are expressed as the TCID50.
Animal Treatment group Examination of faeces samples – haemagglutination assay
Day 21 Day 24 Day 26 Day 28 Day 31 Day 33 Day 35
1 Vaccinated <102.1 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1
2 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1
3 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1
4 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1
5 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1 <102.1
6 Control <102.1 <102.1 102.8 104.8 103.8 103.8 102.8
7 <102.1 <102.1 <102.1 103.8 104.8 102.8 103.1
Table 5
Geometric mean antibody titres against CAV-2 by time period and treatment group.
Titres are expressed as the reciprocal of dilutions.
Treatment group Virus neutralising antibody titres
Day 0 Day 21 Day 35
Vaccinated (n = 10) <2 21 181
Controls (n = 10) <2 <2 119
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dice observed. Elevated temperatures were observed in both con-
trol dogs on day three to six following challenge (peak
temperatures 40.0 C and 39.8 C, respectively). Both dogs were
euthanased prior to study completion ﬁve and six days after chal-
lenge according to prescribed endpoints. No abnormal clinical
observations were observed in vaccinated dogs after challenge,
except for a slight temperature increase above the upper range
limit (39.6 C) in one vaccinated dog six days after challenge.
Antibody titres to CAV-1 and CAV-2 were ﬁrst detected in vac-
cinated dogs on day 21 and continued to rise until day 42 when
sampling ceased. Controls remained sero-negative until after chal-
lenge on day 21, no samples were obtained after challenge as both
control dogs were euthanased prior to study completion (Table 4).
Canine adenovirus type 2
No abnormal clinical observations were observed in the period
following administration of vaccine or control product, with all
dogs remaining in good health. Rectal temperatures remained
within the physiological range during the vaccination phase and
also during the 14 day period following challenge administration.
Following challenge no abnormal clinical symptoms were observed
in vaccinated dogs, but all controls showed signs of infection with
nasal and ocular discharge, depression and coughing seen most fre-
quently. The mean total score of abnormal clinical observations
was signiﬁcantly higher in control (10.1; range 6–15) than vacci-
nated dogs (0.0; P < 0.0001).
Antibody titres to CAV-2 were ﬁrst detected in vaccinated dogs
on day 21 and continued to rise until day 42 when sampling
ceased. Controls remained sero-negative until after challenge on
day 21, sero-converting by day 35 (Table 5).
Analysis of nasal swabs showed that none of the vaccinated or
control dogs had virus in their nasal cavities prior to challenge
on day 21 (titres were less than 102.1 TCID50/mL which is consid-
ered negative). Following challenge virus was re-isolated from ﬁve
vaccinated and seven control dogs; virus titres ranged from 102.1 to
103.8 TCID50/mL in vaccinates and 102.1 to 106.1 TCID50/mL in con-
trol dogs. The number of days of viral shedding was signiﬁcantly
higher in control (Least Squares Mean (LSM) = 4.7) than in
vaccinated (LSM = 0.9) dogs (P < 0.0001). The area under the curveTable 4
Geometric mean antibody titres against CAV-1 and CAV-2, by time period and
treatment group. Titres are expressed as the reciprocal dilution of sera.
Treatment group Virus neutralising antibody titres
Day 0 Day 21 Day 42
CAV-1 CAV-2 CAV-1 CAV-2 CAV-1 CAV-2
Vaccinated (n = 5) <2 <2 18.4 32.0 147.0 128.0
Controls (n = 2) <2 <2 <2 <2 NA NA
NA – both control dogs euthanased prior to sample collection day.of CAV-2 virus titres was also signiﬁcantly higher in non-vacci-
nated (back-transformed LSM = 23.9) than in vaccinated (back-
transformed LSM = 11.7) dogs (P < 0.0001).Discussion
In this paper we have demonstrated a rapid three week onset of
immunity following a single dose of a multivalent vaccine to sero-
negative dogs at minimum age and subsequent protection of vac-
cinated animals following virulent challenge with heterologous
isolates of canine distemper, canine adenovirus (types 1 and 2)
and canine parvovirus.
As has been previously described [17,18], infection of non-vac-
cinated dogs with the respective CDV, CPV, CAV-1 or CAV-2 viruses
resulted in speciﬁc clinical signs, mortality, leucopoenia or virus
shedding. The non-vaccinated dogs in each study remained sero-
negative at the pre-challenge sampling time point thus demon-
strating that no concurrent infection occurred, and if completing
the study they were found to sero-convert at the subsequent sam-
pling time point after challenge. In contrast, in each of the four
studies all vaccinated dogs were found to have (positive) antibody
titres to the respective challenge virus by three weeks following
the single vaccination; the antibody titres obtained contributed
to protection against virulent challenge with CPV, CDV, CAV-1
and CAV-2.
The successful sero-conversion of dogs in each of the four stud-
ies to vaccination, with generation of protective antibodies, is in
contrast to other studies with puppies that had maternally derived
antibodies prior to vaccination [19]. Maternally derived immunity
is considered the primary cause of vaccine failure in young dogs
[20–22]. To overcome interference by maternally derived antibod-
ies, puppies are recommended to be vaccinated repeatedly
between 6 and 16 weeks of age. In the four studies reported here,
dogs were sero-negative prior to vaccination and thus only one
vaccination was required to result in full protection.
Protection against CPV was assessed by challenge with a heter-
ologous CPV2b strain. There are currently two more antigenic
types of CPV circulating in the ﬁeld, CPV2a and CPV2c. They differ
genetically from CPV2b through point mutations [23]. In vitro,
cross serum-neutralisation and haemagglutination studies have
shown that antibody titres against heterologous antigenic types
can be signiﬁcantly lower than those to homologous types. Despite
106 S. Wilson et al. / Trials in Vaccinology 3 (2014) 102–106these differences however no deﬁnitive evidence for a lack of
cross-protection against parvovirosis has been found in vivo to
date [21].
Conclusion
A single administration of a minimum titre, multivalent vaccine
to dogs of six weeks of age is efﬁcacious and prevents both clinical
signs and mortality caused by CAV-1 and CDV; prevents clinical
signs and signiﬁcantly reduces virus shedding caused by CAV-2;
and prevents clinical signs, leucopoenia and viral excretion caused
by CPV.
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